[1]
|
Emerit, J., Beaumont, C. and Trivin, F. (2001) Iron metabolism, free radicals, and oxidative injury. Biomedicine & Pharmacotherapy, 55, 333-339.
doi:10.1016/S0753-3322(01)00068-3
|
[2]
|
Pootrakul, P., Breuer, W., Sametband, M., Sirankapracha, P., Hershko, C. and Cabantchik, Z.I. (2004) Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator. Blood, 104, 1504- 1510. doi:10.1182/blood-2004-02-0630
|
[3]
|
Hershko, C. (2007) Iron loading and its clinical implications. American Journal of Hematology, 82, 1147-1148.
doi:10.1002/ajh.21070
|
[4]
|
Esposito, B. P., Breuer, W., Sirankapracha, P., Pootrakul, P., Hershko, C. and Cabantchik, Z.I. (2003) Labile plas- ma iron in iron overload: Redox activity and susceptibility to chelation. Blood, 102, 2670-2677.
doi:10.1182/blood-2003-03-0807
|
[5]
|
Hershko, C.M., Link, G.M., Konijn, A.M. and Cabantchik, Z.I. (2005) Iron chelation therapy. Current Hematology Reports, 4, 110-116.
|
[6]
|
Taher, A.T., Musallam, K.M. and Inati, A. (2009) Iron overload: Consequences, assessment, and monitoring. He- moglobin, 33, S46-57. doi:10.3109/03630260903346676
|
[7]
|
Miskin, H., Yaniv, I., Berant, M., Hershko, C. and Tamary, H. (2003) Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. European Journal of Haematology, 70, 398-403. doi:10.1034/j.1600-0609.2003.00075.x
|
[8]
|
Modell, B., Khan, M. and Darlison, M. (2000) Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register. Lancet, 355, 2051-2052.
doi:10.1016/S0140-6736(00)02357-6
|
[9]
|
Lau, Y.L., Chan, L.C., Chan, Y.Y., Ha, S.Y., Yeung, C.Y., Waye, J.S. and Chui, D.H. (1997) Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong—Implications for population screening. The New England Journal of Medicine, 336, 1298-1301.
doi:10.1056/NEJM199705013361805
|
[10]
|
Economou, M., Printza, N., Teli, A., Tzimouli, V., Tsatra, I., Papachristou, F. and Athanassiou-Metaxa, M. (2010) Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematologica, 123, 148-152. doi:10.1159/000287238
|
[11]
|
Pippard, M.J. (1987) Iron overload and iron chelation therapy in thalassaemia and sickle cell haemoglobino- pathies. Acta Haematologica, 78, 206-211.
doi:10.1159/000205876
|
[12]
|
Collins, A.F., Fassos, F.F., Stobie, S., Lewis, N., Shaw, D., Fry, M., Templeton, D.M., McClelland, R.A., Koren, G. and Olivieri, N.F. (1994) Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl- 3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood, 83, 2329-2333.
|
[13]
|
Freeman, A.P., Giles, R.W., Berdoukas, V.A., Talley, P.A. and Murray, I.P. (1989) Sustained normalization of cardiac function by chelation therapy in thalassaemia major. Clinical and Laboratory Haematology, 11, 299- 307. doi:10.1111/j.1365-2257.1989.tb00227.x
|
[14]
|
Brittenham, G.M. (2003) Iron chelators and iron toxicity. Alcohol, 30, 151-158.
doi:10.1016/S0741-8329(03)00101-0
|
[15]
|
Peterson, C.M., Graziano, J.H., Grady, R.W., Jones, R.L., Vlassara, H.V., Canale, V.C., Miller, D.R. and Cerami, A. (1976) Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major. British Journal of Haematology, 33, 477-485.
doi:10.1111/j.1365-2141.1976.tb03566.x
|
[16]
|
Peterson, C.M., Graziano, J.H., Grady, R.W., Jones, R.L., Markenson, A., Lavi, U., Canale, V., Gray, G.F., Cerami, A. and Miller, D.R. (1979) Chelation therapy in beta- thalassemia major: A one-year double blind study of 2,3- dihydroxybenzoic acid. Experimental Hematology, 7, 74- 80.
|
[17]
|
Pippard, M.J., Jackson, M.J. and Modell, C.B. (1988) Subcutaneous diethylene triamine pentaacetic acid: Comparison with desferrioxamine in thalassemic patients with iron overload. Birth Defects Original Article Series, 23, 105-109.
|
[18]
|
Grady, R.W., Salbe, A.D., Hilgartner, M.W. and Giardina, P.J. (1994) Results from a phase I clinical trial of HBED. Advances in Experimental Medicine and Biology, 356, 351-359. doi:10.1007/978-1-4615-2554-7_37
|
[19]
|
Rai, B.L., Dekhordi, L.S., Khodr, H., Jin, Y., Liu, Z. and Hider, R.C. (1998) Synthesis, physicochemical properties, and evaluation of N-substituted-2-al kyl-3-hydroxy-4(1H)- pyridinones. Journal of Medicinal Chemistry, 41, 3347- 3359. doi:10.1021/jm9707784
|
[20]
|
Srichairatanakool, S., Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalpong, C. and Fucharoen, S. (2006) Iron-chelating and free-radical scavenging activities of microwave-processed green tea in iron overload. Hemoglobin, 30, 311-327. doi:10.1080/03630260600642666
|
[21]
|
Thephinlap, C., Ounjaijean, S., Khansuwan, U., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2007) Epigallocatechin-3-gallate and epicatechin-3-gallate from green tea decrease plasma non-transferrin bound iron and ery- throcyte oxidative stress. Medicinal Chemistry, 3, 289- 296. doi:10.2174/157340607780620608
|
[22]
|
Srichairatanakool, S., Thephinlap, C., Phisalaphong, C., Porter, J.B. and Fucharoen, S. (2007) Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma. Medicinal Chemistry, 3, 469-474.
doi:10.2174/157340607781745447
|
[23]
|
Thephinlap, C., Phisalaphong, C., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2009) Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Medicinal Chemistry, 5, 474- 482. doi:10.2174/157340609789117912
|
[24]
|
Saewong, T., Ounjaijean, S., Mundee, Y., Pattanapanyasat, K., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2010) Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice. Medicinal Chemistry, 6, 57-64.
doi:10.2174/157340610791321479
|
[25]
|
Bergeron, R.J., Wiegand, J. and Brittenham, G.M. (1999) HBED: The continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood, 93, 370-375.
|
[26]
|
Porter, J.B. (1996) Evaluation of new iron chelators for clinical use. Acta Haematologic, 95, 13-25.
doi:10.1159/000203852
|
[27]
|
Srichairatanakool, S., Pangjit, K. and Phisalaphong, C. (2009) Characterization and investigation of chelating activity of a novel iron chelator: 1-(N-acetyl-6-aminohexyl) -3-hydroxypyridin-4-one. Thailand Patent No. 0901000 799.
|
[28]
|
Pangjit, K., Banjerdpongchai, R., Phisalaphong, C., Fu- charoen, S. and Srichairatanakool, S. (2012) Efficacy of 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-4-one (CM1) in treatment of iron-loaded hepatocyte cultures. Advances in Bioscience and Biotechnology, 3, 1060-1067.
doi:10.4236/abb.2012.327129
|
[29]
|
Jamsai, D., Zaibak, F., Khongnium, W., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Fucharoen, S., Williamson, R. and Ioannou, P.A. (2005) A humanized mouse model for a common beta0-thalassemia mutation. Genomics, 85, 453-461. doi:10.1016/j.ygeno.2004.11.016
|
[30]
|
Jamsai, D., Zaibak, F., Vadolas, J., Voullaire, L., Fowler, K.J., Gazeas, S., Peters, H., Fucharoen, S., Williamson, R. and Ioannou, P.A. (2006) A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. Genomics, 88, 309-315. doi:10.1016/j.ygeno.2006.03.009
|
[31]
|
Valerio Jr., L.G. and Petersen, D.R. (2000) Characterization of hepatic iron overload following dietary administration of dicyclopentadienyl iron (Ferrocene) to mice: Cellular, biochemical, and molecular aspects. Experimental and Molecular Pathology, 68, 1-12.
doi:10.1006/exmp.1999.2278
|
[32]
|
Ounjaijean, S., Thephinlap, C., Khansuwan, U., Phisalapong, C., Fucharoen, S., Porter, J.B. and Srichairatanakool, S. (2008) Effect of green tea on iron status and oxidative stress in iron-loaded rats. Medicinal Chemistry, 4, 365-370. doi:10.2174/157340608784872316
|
[33]
|
Kuross, S.A., Rank, B.H. and Hebbel, R.P. (1988) Excess heme in sickle erythrocyte inside-out membranes: Possible role in thiol oxidation. Blood, 71, 876-882.
|
[34]
|
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72, 248-254.
doi:10.1016/0003-2697(76)90527-3
|
[35]
|
Singh, S., Hider, R.C. and Porter, J.B. (1990) A direct method for quantification of non-transferrin-bound iron. Analytical Biochemistry, 186, 320-323.
doi:10.1016/0003-2697(90)90088-Q
|
[36]
|
Rebouche, C.J., Wilcox, C.L. and Widness, J.A. (2004) Microanalysis of non-heme iron in animal tissues. Journal of Biochemical and Biophysical Methods, 58, 239- 251. doi:10.1016/j.jbbm.2003.11.003
|
[37]
|
Grotto, D., Santa Maria, L.D., Boeira, S., Valentini, J., Charao, M.F., Moro, A.M., Nascimento, P.C., Pomblum, V.J. and Garcia, S.C. (2007) Rapid quantification of ma- londialdehyde in plasma by high performance liquid chromatography-visible detection. Journal of Pharmaceutical and Biomedical Analysis, 43, 619-624.
doi:10.1016/j.jpba.2006.07.030
|
[38]
|
Gomes, A.T., Bastos, C.G., Afonso, C.L., Medrado, B.F. and Andrade, Z.A. (2006) How variable are hydroxy- proline determinations made in different samples of the same liver? Clinical Biochemistry, 39, 1160-1163.
doi:10.1016/j.clinbiochem.2006.08.002
|
[39]
|
Bancroft, J.S.A. (1982) Theory and practice of histological techniques. 2nd Edition, Churchill-Livingston, New York, 131-135.
|
[40]
|
Aisen, P., Enns, C. and Wessling-Resnick, M. (2001) Chemistry and biology of eukaryotic iron metabolism. The International Journal of Biochemistry & Cell Biology, 33, 940-959. doi:10.1016/S1357-2725(01)00063-2
|
[41]
|
Crichton, R.R. and Ward, R.J. (2003) An overview of iron metabolism: Molecular and cellular criteria for the selection of iron chelators. Current Medicinal Chemistry, 10, 997-1004. doi:10.2174/0929867033457566
|
[42]
|
Conrad, M.E. and Umbreit, J.N. (2002) Pathways of iron absorption. Blood Cells, Molecules and Diseases, 29, 336- 355. doi:10.1006/bcmd.2002.0564
|
[43]
|
Pippard, M.J., Callender, S.T., Warner, G.T. and Weatherall, D.J. (1979) Iron absorption and loading in beta-tha- lassaemia intermedia. Lancet, 2, 819-821.
doi:10.1016/S0140-6736(79)92175-5
|
[44]
|
McLaren, G.D., Nathanson, M.H., Jacobs, A., Trevett, D. and Thomson, W. (1991) Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. Journal of Laboratory and Clinical Medicine, 117, 390-401.
|
[45]
|
Raja, K.B., Simpson, R.J. and Peters, T.J. (1994) Intestinal iron absorption studies in mouse models of iron- overload. British Journal of Haematology, 86, 156-162.
doi:10.1111/j.1365-2141.1994.tb03267.x
|
[46]
|
Longueville, A. and Crichton, R.R. (1986) An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Biochemical Pharmacology, 35, 3669-3678.
doi:10.1016/0006-2952(86)90650-7
|
[47]
|
Braumann, A., Wulfhekel, U., Dullmann, J. and Nielsen, P. (1992) Iron overload of the bone marrow by trime- thylhexanoyl-ferrocene in rats. Acta Anatomica (Basel), 144, 285-295. doi:10.1159/000147318
|
[48]
|
Florence, A., Ward, R.J., Peters, T.J. and Crichton, R.R. (1992) Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat. Biochemical Pharmacology, 44, 1023-1027. doi:10.1016/0006-2952(92)90363-N
|
[49]
|
Van Wyck, D.B., Popp, R.A., Foxley, J., Witte, M.H., Witte, C.L. and Crosby, W.H. (1984) Spontaneous iron overload in alpha-thalassemic mice. Blood, 64, 263-266.
|
[50]
|
Garrick, L.M., Strano-Paul, L.A., Hoke, J.E., Kirdani- Ryan, L.A., Alberico, R.A., Everett, M.M., Bannerman, R.M. and Garrick, M.D. (1989) Tissue iron deposition in untransfused beta-thalassemic mice. Experimental Hema- tology, 17, 423-428.
|
[51]
|
Chua, A.C., Ingram, H.A., Raymond, K.N. and Baker, E. (2003) Multidentate pyridinones inhibit the metabolism of nontransferrin-bound iron by hepatocytes and hepatoma cells. European Journal of Biochemistry, 270, 1689- 1698. doi:10.1046/j.1432-1033.2003.03525.x
|
[52]
|
Chua, A.C., Olynyk, J.K., Leedman, P.J. and Trinder, D. (2004) Nontransferrin-bound iron uptake by hepatocytes is increased in the Hfe knockout mouse model of hereditary hemochromatosis. Blood, 104, 1519-1525.
doi:10.1182/blood-2003-11-3872
|
[53]
|
Porter, J.B., Rafique, R., Srichairatanakool, S., Davis, B.A., Shah, F.T., Hair, T. and Evans, P. (2005) Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use. Annals of the New York Academy of Sciences, 1054, 155- 168. doi:10.1196/annals.1345.018
|
[54]
|
Liuzzi, J.P., Aydemir, F., Nam, H., Knutson, M.D. and Cousins, R.J. (2006) Zip14 (Slc39a14) mediates non- transferrin-bound iron uptake into cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 13612-13617.
doi:10.1073/pnas.0606424103
|
[55]
|
Shinar, E. and Rachmilewitz, E.A. (1990) Oxidative denaturation of red blood cells in thalassemia. Seminars in Hematology, 27, 70-82.
|
[56]
|
Scott, M.D., van den Berg, J.J., Repka, T., Rouyer-Fessard, P., Hebbel, R.P., Beuzard, Y. and Lubin, B.H. (1993) Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. Journal of Clinical Investigation, 91, 1706-1712.
doi:10.1172/JCI116380
|
[57]
|
Browne, P.V., Shalev, O., Kuypers, F.A., Brugnara, C., Solovey, A., Mohandas, N., Schrier, S.L. and Hebbel, R.P. (1997) Removal of erythrocyte membrane iron in vivo ameliorates the pathobiology of murine thalassemia. Jour- nal of Clinical Investigation, 100, 1459-1464.
doi:10.1172/JCI119666
|
[58]
|
Andrews, N.C. (1999) Disorders of iron metabolism. The New England Journal of Medicine, 341, 1986-1995.
doi:10.1056/NEJM199912233412607
|
[59]
|
Bacon, B.R. and Britton, R.S. (1989) Hepatic injury in chronic iron overload. Role of lipid peroxidation. Che- mico-Biological Interactions, 70, 183-226.
doi:10.1016/0009-2797(89)90045-8
|
[60]
|
Jensen, P.D. (2004) Evaluation of iron overload. British Journal of Haematology, 124, 697-711.
doi:10.1111/j.1365-2141.2004.04838.x
|
[61]
|
Ramm, G.A. and Ruddell, R.G. (2005) Hepatotoxicity of iron overload: Mechanisms of iron-induced hepatic fibrogenesis. Seminars in Liver Disease, 25, 433-449.
doi:10.1055/s-2005-923315
|
[62]
|
Popper, H. and Uenfriend, S. (1970) Hepatic fibrosis. Correlation of biochemical and morphologic investigations. The American Journal of Medicine, 49, 707-721.
doi:10.1016/S0002-9343(70)80135-8
|
[63]
|
Kushner, J.P., Porter, J.P. and Olivieri, N.F. (2001) Secondary iron overload. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 47-61.
|
[64]
|
Weatherall, D.J. (1998) Pathophysiology of thalassaemia. Baillière’s Clinical Haematology, 11, 127-146.
doi:10.1016/S0950-3536(98)80072-3
|
[65]
|
Bartfay, W.J. and Bartfay, E. (2000) Iron-overload cardiomyopathy: evidence for a free radical—Mediated me- chanism of injury and dysfunction in a murine model. Biological Research for Nursing, 2, 49-59.
doi:10.1177/109980040000200106
|
[66]
|
Schellhammer, P.F., Engle, M.A. and Hagstrom, J.W. (1967) Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation, 35, 631-637. doi:10.1161/01.CIR.35.4.631
|
[67]
|
Kremastinos, D.T., Toutouzas, P.K., Vyssoulis, G.P., Venetis, C.A. and Avgoustakis, D.G. (1984) Iron overload and left ventricular performance in beta thalassemia. Acta Cardiologica, 39, 29-40.
|
[68]
|
Sonakul, D., Pacharee, P. and Thakerngpol, K. (1988) Pathologic findings in 76 autopsy cases of thalassemia. Birth Defects Original Article Series, 23, 157-176.
|
[69]
|
Bannerman, R.M., Keusch, G., Kreimer-Birnbaum, M., Vance, V.K. and Vaughan, S. (1967) Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria. The American Journal of Medicine, 42, 476-486.
doi:10.1016/0002-9343(67)90276-8
|
[70]
|
Aldouri, M.A., Wonke, B., Hoffbrand, A.V., Flynn, D.M., Ward, S.E., Agnew, J.E. and Hilson, A.J. (1990) High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica, 84, 113- 117. doi:10.1159/000205046
|
[71]
|
Kremastinos, D.T., Tiniakos, G., Theodorakis, G.N., Katritsis, D.G. and Toutouzas, P.K. (1995) Myocarditis in beta-thalassemia major. A cause of heart failure. Circulation, 91, 66-71. doi:10.1161/01.CIR.91.1.66
|
[72]
|
Cohen, A., Martin, M. and Schwartz, E. (1984) Depletion of excessive liver iron stores with desferrioxamine. British Journal of Haematology, 58, 369-373.
doi:10.1111/j.1365-2141.1984.tb06096.x
|